Living With Prostate Cancer

Investigators unveil metastatic prostate cancer’s genomic landscape

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Localized prostate cancer that is diagnosed before it has a chance to spread typically responds well to surgery or radiation. But when a tumor metastasizes and sends malignant cells elsewhere in the body, the prognosis worsens. Better treatments for men with metastatic prostate cancer are urgently needed. In 2018, scientists advanced toward that goal by […]

A mix of treatments may extend life for men with aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

For men diagnosed with aggressive cancer that’s confined to the prostate and nearby tissues, the overarching goal of treatment is to keep the disease from spreading (or metastasizing) in the body. Doctors can treat these men with localized therapies, such as surgery and different types of radiation that target the prostate directly. And they can […]

Newer drugs are improving survival for men with metastatic prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men with prostate cancer that has spread outside the gland now have several newer drug options available for treatment, and research has found that taking any of them is likely to improve survival duration.

New study downplays potential risk of dementia and Alzheimer’s disease among elderly men treated with hormonal therapy for prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

The male hormone testosterone contributes to normal brain function, and some research links memory loss in older men to testosterone declines that occur naturally with aging. However, testosterone is also like jet fuel for prostate tumors, causing them to grow faster, so during cancer treatment doctors will often give hormonal therapies that suppress its activities […]

Study investigates treatment regret among prostate cancer survivors

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Charles Schmidt As they get older, do men with prostate cancer come to regret the treatment decisions they made? A new study of men diagnosed during the mid-1990s indicates that some of them will. Richard Hoffman, a professor of internal medicine and epidemiology at the University of Iowa Carver College of Medicine in Iowa City, […]

Combination hormonal therapy boosts survival in men with aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Charlie Schmidt A standard approach for treating aggressive prostate cancer is to give therapies that block testosterone, a tumor-stimulating hormone. Should initial hormonal therapies fail, doctors can switch to other drugs that suppress testosterone in different ways. One of them, a drug called abiraterone, has been shown to significantly extend lifespans in men who have […]

Yoga improves treatment-related symptoms in men with prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Charlie Schmidt Decades of research show that yoga can reduce the emotional and physical fatigue brought on by cancer treatment. Now researchers have shown for the first time that’s also true specifically for men being treated for prostate cancer. Men who took a yoga class twice a week during treatment reported less fatigue, fewer sexual […]

Combining surgery, radiation, and hormonal therapy dramatically extends survival in men with advanced prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Charlie Schmidt In April, scientists reported encouraging results from a pilot study of men with metastatic prostate cancer, or cancer that has spread beyond the prostate gland. Long considered incurable, these advanced cancers are usually treated by giving men systemic drugs that target new tumors forming in the body. The scientists who led this new […]

Adding hormonal therapy to radiation lengthens survival in men with recurring prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

High-grade cancer that’s still confined to the prostate is generally treated surgically. But a third of the men who have their cancerous prostates removed will experience a rise in blood levels of prostate-specific antigen (PSA). This is called PSA recurrence. And since detectable PSA could signal the cancer’s return, doctors will often treat it by […]

New study recommends immediate radiation when PSA Levels spike after prostate cancer surgery

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Following surgery to remove a cancerous prostate gland, some men experience a biochemical recurrence, meaning that prostate-specific antigen (PSA) has become detectable in their blood. Since only the prostate releases PSA, removing the gland should drop this protein to undetectable levels in the body. Detecting PSA could signify that prostate cancer cells are lingering, and […]